-
RMAT designation granted by FDA CBER for IMA203 cell therapy in multiple PRAME-expressing tumors including cutaneous and uveal melanoma, ovarian cancer and other cancer types
-
Regulatory activities underway with an initial focus on a registration-directed trial in melanoma as step one to leverage the full breadth of PRAME
Cord Blood Banking Leader Cryo-Cell Reports Fiscal Third Quarter 2023 Financial Results
October 12, 2023, OLDSMAR, Fla. — Cryo-Cell International, Inc. (NYSE American LLC Symbol: CCEL),the world’s first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal third quarter ended August 31, 2023.
Financial Results
Revenue
Consolidated revenues for the third quarter of fiscal 2023 were $7.87 million compared to $7.68 million for the third quarter of fiscal 2022. The revenues for the third quarter of fiscal 2023 consisted of $7.86 million in processing and storage fees, $3,000 in product revenue and $4,000 in public banking revenue compared to $7.52 million in processing and storage fees, $21,000 in product revenue and $138,000 in public banking revenue for the third quarter of fiscal 2022. [Read more…]
Editas Medicine Granted RMAT Designation for EDIT-301 for Severe Sickle Cell Disease
October 17, 2023, CAMBRIDGE, Mass. — Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to EDIT-301, an investigational, gene editing medicine, for the treatment of severe sickle cell disease (SCD). [Read more…]
Bayer to Advance Cell Therapy Manufacturing with $250M, All-Electric Facility
-
$250 million (USD) plant will help produce transformational cell and gene therapies on a global scale
-
Creating readiness for first production runs of potential commercial launches, including bemdaneprocel (BRT-DA01), BlueRock Therapeutics’ investigational cell therapy for Parkinson’s disease as well as product supply for late-stage clinical trials
-
New plant helps break industry-wide bottleneck in manufacturing capacity for regenerative medicines
-
100,000 sq. ft. building advances Bayer’s sustainability efforts – first fully electric manufacturing plant in Bayer’s global pharmaceutical manufacturing network
Chinese Patent Granted for CytoMed Therapeutics’ Licensed iPSC-Based Technology
SINGAPORE — CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor-derived cell-based allogeneic immunotherapies for the treatment of various cancers, today announced that its exclusively licensed induced pluripotent stem cell (iPSC)-based technology has been granted a patent by the China National Intellectual Property Administration (CNIPA). [Read more…]
- « Previous Page
- 1
- …
- 34
- 35
- 36
- 37
- 38
- …
- 116
- Next Page »